Abstract

Purpose: The exact etiology of mesenteric panniculitis (MP) is still unknown and has been discussed in relation to different causes. The aim of this retrospective study was to evaluate a coherence between MP and malignancy.

Materials and Methods: Retrospective analysis of consecutive CT abdomen examinations of 5595 patients in terms of MP over a period of 3 years was performed. To make the diagnosis of MP, three of five typical signs were obligatory: hyperdense mass lesion with intercalated nodules, a “fat-ring sign” or halo sign, a hyperdense pseudocapsule and displacement of bowel loops. The patient cohort (mean age: 64.7 years) consisted of 1974 (35.2 %) patients with histologically confirmed cancer and 3621 patients (64.8 %) without known underlying oncological disease.

Results: A total of 143 cases were diagnosed with MP (2.55 %). The average age of patients was 69.9 years with a male to female ratio of 2:1. In this group oncological disease was confirmed in 107 patients (74.8 %). In 36 patients with MP (25.2 %), no malignancy was present. In the group of patients with an underlying oncological disease, the prevalence of MP was 5.42 % and was significantly higher (p < 0.005) than in the patients with MP and without an oncological disease. The highest prevalence of MP (29 cases) was observed in non-Hodgkin lymphoma (22.6 %). The statistically calculated risk of a tumor disease in this collective is about 5 times higher if MP was demonstrated (p < 0.001).

Conclusion: Based on the data of the collective, the risk of malignancy is five times higher in the presence of MP than in an inconspicuous mesentery. MP seems to frequently occur with non-Hodgkin lymphoma. MP can be seen on the basis of typical morphological features on the CT image. MP must be differentiated from a wide range of benign and malignant diseases of the mesentery.

Key points:

> Mesenteric panniculitis can be diagnosed with CT.
> In the case of accidentally diagnosed mesenteric panniculitis, a possible malignant cause should be ruled out in the differential diagnosis.

Citation Format:

Das Durchschnittsalter der Patienten betrug 69.9 Jahre bei einem Verhältnis des männlichen zum weiblichen Geschlecht von 2:1. In dieser Gruppe war bei 107 Patienten (74.8 %) eine onkologische Erkrankung gesichert. Bei 36 Patienten mit einer MP (25.2 %) lag kein Malignom vor. Im Patientenkollektiv mit einer onkologischen Grunderkrankung betrug die Prävalenz der MP 5,42 % und war somit signifikant höher (p < 0.005) als in der Patientengruppe mit MP ohne onkologische Erkrankung. Die höchste Prävalenz der MP mit 29 Fällen wurde beim Non-Hodgkin-Lymphom beobachtet (22.6 %). Das statistisch berechnete Risiko für eine Tumorerkrankung liegt in diesem Kollektiv ca. fünfmal so hoch, falls eine MP nachgewiesen wurde (p < 0.001).


Introduction

Mesenteric panniculitis (MP) is a rare inflammatory disease of the adipose tissue of the mesentery with specific morphological signs in computed tomography (CT) [1]. MP is a type of sclerosing mesenteritis which is an IgG4-related sclerosing disease (ISD) [2]. The disease is characterized by necrosis, inflammatory infiltration, and fibrosis of the mesenteric adipose tissue, with these three dominant processes occurring to different degrees [3, 4]. The preferred location is the root of the small bowel mesentery [5, 6]. Inflammatory, autoimmune, postoperative, and malignant causes are discussed with respect to etiology [3, 5, 6]. Although there are no specific clinical symptoms of MP, generalized abdominal pain is common. As a result of the broad use of CT, MP is increasingly diagnosed as an incidental finding in asymptomatic patients. CT is an important examination method for diagnosing MP. MP presents with specific signs on a CT image. In addition to an increase in the density of the mesentery with intercalated nodules, a “fat-ring sign” as a halo around vessels, formation of a pseudocapsule and displacement of bowel loops are signs of MP [7, 8]. According to the literature, the prevalence of MP is between 0.16 % and 2.4 % [6, 7, 9, 10]. MP occurs in every age group, but primarily in the 6th to 7th decade of life. The male to female ratio is 2:1 [6, 11]. The differential diagnoses of MP are a broad spectrum of inflammatory, infectious, neoplastic, vascular-ischemic and idiopathic diseases [12]. In particular, NHL must be ruled out in the case of neoplasia [13]. The primary goal of this retrospective study was to evaluate a coherence between MP and an underlying malignant disease.

Materials and Methods

The study included 5595 multislice computed tomography (MSCT) abdomen examinations acquired between January 2010 and December 2013 (3004 data sets from a tertiary care hospital and 2591 from a radiology practice). The inclusion criterion for the RIS-based data search was all CT abdomen examinations with a scanning field from the diaphragm to the lower abdomen so that visualization of the entire root of the mesentery was ensured. Follow-up examinations, examinations of the upper abdomen, and CT scans of the pelvis were not included. The gender ratio in the patient population was almost equal: 2863 women (51 %) and 2732 men (49 %). The average age was 64.7 +/- 15.13 years (age range: 4 – 100 years). The database search was performed in the RIS/PACS system with a search filter. The CT data sets were blinded using identification numbers and were retrospectively and systematically examined for MP by a radiology specialist with multi-year experience in abdominal CT. All CT scans were acquired with an MSCT unit (Brilliance CT 16, Philips Healthcare und Activion CT 16, Toshiba) according to standard clinical protocols. Images were acquired with an axial scan orientation and in the craniocaudal direction with a collimation of 16 x 1.5 mm, a rotation time of 0.75 s, and a pitch factor of 0.94. Automatic tube current modulation. Standard coronal and sagittal reconstructions in the soft-tissue window (W: 350, C: 50) with a reconstruction interval of 5 mm were generated from the MSCT data sets. 90 % of the examinations (5053) were examined with an i.v. contrast agent. No i.v. contrast agent was used in 10 % of the examinations (542). 5595 MSCT data sets were thoroughly examined for the typical signs of MP. At least three of five criteria had to be present for a diagnosis of MP. In addition to a diffuse increase in the density of the mesentery with intercalated nodules and a consecutive space-occupying effect resulting in displacement of the adjacent bowel loops, a halo around the mesenteric vessels and possible capsule formation had to be present. The tumoral pseudocapsule is visualized as a narrow band of compression and limits the process with respect to normal mesenteric adipose tissue (Fig. 1, Table 1). Patients were first evaluated with respect to known tumor diseases. Statistical evaluations were performed with IBM SPSS Statistics (Version 23, Chicago, IL, USA) and EXCEL 2010 (Microsoft). Data were presented as mean ± standard deviation (SD). Multivariate regression analyses including the hazard ratios were performed. The non-parametric Mann-Whitney U-test for independent variables and the Wilcoxon signed rank test for dependent variables were used.

Results

143 of 5595 retrospectively examined MSCT data sets (2.55 %) showed typical signs of MP. 87 data sets came from the tertiary care hospital and 56 MSCT data sets from the radiological practice. The male to female ratio was approx. 60 % to 40 % (90/143 male, 53/143 female). The average age was 69.9 +/- 10.65 years (range: 32 – 92 years). 3 signs of MP could be reliably diagnosed in 38/143 cases (26.6 %), 4 signs in 54/143 (37.8 %), and all signs in 51/143 patients (35.8 %) on computed tomography (Fig. 2). An increase in the density of the mesentery with mean values of -67 HU +/- 18 HU was seen in all patients (143) in our cohort. Intercalated nodules with a mean cross-sectional diameter of 8 mm (+/- 4 mm) were detected in 142 patients (97.2 %). A space-occupying effect with displacement of the adjacent bowel loops was diagnosed in 78 % of cases (111), formation of a
Pseudocapsule in 70% of cases (100), and a halo sign in 86 patients (60%).

A tumor disease was confirmed in 1974/5595 patients (35.2%). The average age in this group was 67.6 +/- 12.55 years (age range: 4 – 100 years). The gender ratio was almost 1:1 (988 men, 986 women). The tumor entities and the frequency distribution are shown in Table 2. A histopathologically confirmed oncological disease with a maximum in the case of lymphoma was present in 107 of the 143 patients with MP (74.8%) at the time of CT evaluation.

In 36/143 patients (25.2%) with diagnosed MP, there was no known tumor disease in the medical history. The average age of these patients was 69.8 +/- 11.13 years (age range: 49 – 92 years). The gender ratio was almost equal 19/36 men (52.8%) and 17/36 women (47.2%). In our patient population MP was significantly more frequently associated with an underlying oncological disease (p < 0.005). The greatest prevalence for MP was seen in the group with lymphoma diseases. 22.65% of patients with confirmed lymphoma disease presented with MP.

Frequency distribution of the diagnostic criteria of MP on the MSCT image shows a tendency toward MP without an associated tumor in our cohort. Therefore, the criteria of increased density and intercalated nodules in the MP cohort with and without tumor disease were not significantly different. The mean cross-sectional diameter of the nodules in the entire cohort was 8 mm (+/- 4 mm). The space-occupying component was seen slightly more frequently in the non-oncological group than in the oncological group (81% (29/36) vs. 77.6% (83/107)). A typical halo sign was diagnosed in 62/107 patients (58%) in the oncological group and in 25/36 patients (69%) in the non-oncological group.

Pseudocapsules were seen more frequently in the non-oncological group (64% (69/107)) than in the oncological group (64% (69/107)). According to the retrospective analysis of our data, the presence of a tumor disease is 5211 (CI 95% 3549 – 7651) times more likely in the case of MP.
Table 2  Frequency of different tumor entities in relation to the overall population as well as occurrence of MP with respect to the tumor entity.

<table>
<thead>
<tr>
<th>Tumor Entity</th>
<th>Frequency Tumor/Overall Population</th>
<th>%</th>
<th>Frequency MP/Tumor Entity</th>
<th>%</th>
<th>Frequency MP with Tumor/MP Overall</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphoma</td>
<td>128/5595</td>
<td>2.26</td>
<td>29/128</td>
<td>22.65</td>
<td>29/143</td>
<td>20.27</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>452/5595</td>
<td>8.07</td>
<td>20/452</td>
<td>4.42</td>
<td>20/143</td>
<td>13.98</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>180/5595</td>
<td>3.21</td>
<td>11/180</td>
<td>6.11</td>
<td>11/143</td>
<td>7.69</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>262/5595</td>
<td>4.68</td>
<td>5/262</td>
<td>1.90</td>
<td>5/143</td>
<td>3.49</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>64/5595</td>
<td>1.14</td>
<td>7/64</td>
<td>10.93</td>
<td>7/143</td>
<td>4.89</td>
</tr>
<tr>
<td>Gastric cancer</td>
<td>110/5595</td>
<td>1.96</td>
<td>5/110</td>
<td>4.54</td>
<td>5/143</td>
<td>3.49</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>108/5595</td>
<td>1.93</td>
<td>3/108</td>
<td>2.77</td>
<td>3/143</td>
<td>2.09</td>
</tr>
<tr>
<td>Bronchial cancer</td>
<td>126/5595</td>
<td>2.25</td>
<td>7/126</td>
<td>5.55</td>
<td>7/143</td>
<td>4.89</td>
</tr>
<tr>
<td>Bladder cancer</td>
<td>79/5595</td>
<td>1.41</td>
<td>5/79</td>
<td>6.32</td>
<td>5/143</td>
<td>3.49</td>
</tr>
<tr>
<td>Melanoma</td>
<td>44/5595</td>
<td>0.78</td>
<td>2/44</td>
<td>4.55</td>
<td>2/143</td>
<td>1.39</td>
</tr>
<tr>
<td>Esophageal cancer</td>
<td>48/5595</td>
<td>0.85</td>
<td>3/48</td>
<td>6.25</td>
<td>3/143</td>
<td>2.09</td>
</tr>
<tr>
<td>Uterine cancer</td>
<td>46/5595</td>
<td>0.66</td>
<td>1/46</td>
<td>2.17</td>
<td>1/143</td>
<td>0.69</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>84/5595</td>
<td>1.50</td>
<td>1/84</td>
<td>1.19</td>
<td>1/143</td>
<td>0.69</td>
</tr>
<tr>
<td>Other</td>
<td>246/5595</td>
<td>4.39</td>
<td>8/264</td>
<td>3.25</td>
<td>8/143</td>
<td>5.59</td>
</tr>
</tbody>
</table>

n = 107/143.

Fig. 3  Distribution of the diagnostic criteria for MP in the entire patient population.

Fig. 4  Frequency of diagnostic criteria of MP in patient population with a tumor disease (107/143).

Fig. 5  Frequency of diagnostic criteria of MP in group of patients without a tumor disease (36/143).
The risk of MP increases with age by 24% per 10 years ($p < 0.02$).

**Discussion**

MP is typically an incidental CT finding in asymptomatic patients or is diagnosed during abdominal surgery [9, 14]. Important diagnostic criteria of MP in abdominal CT are increased density of the mesentery, a "fat-ring sign", a pseudocapsule, intercalated nodules, and displacement of the bowel loops. In the present study at least one diffuse increase in density of the affected mesentery with intercalated nodules was found in all patients with a diagnosis of MP. Intercalated nodules in the affected mesentery with an average size of less than 10 mm are observed in most patients [10, 15]. Wilkes et al. postulated an increased risk for occult malignancy in nodules with a size of at least 12 mm and a lack of "fat-ring sign" or halo sign [1]. In our patient population 58% of cases of MP with an underlying oncological disease had a "fat-ring sign" or a halo sign, while the sign was seen in 69% of cases in the group of MP without tumor disease. A significant difference in nodule size in MP with and without tumor association was not seen in our cohort (Table 3). With a mean value of -67 HU, the increase in density in the affected mesentery in our patient population was significantly higher compared to unaffected adipose tissue (-109) and is comparable with the data in the literature [9, 10]. Displacement of adjacent bowel loops was identified in 77% of cases, a pseudocapsule in 70% of cases, and a "fat-ring sign" in 60.1% of cases. Studies by Daskalogianaki and Sabate showed similar results regarding the occurrence of a pseudocapsule and a "fat-ring sign" and describe changes that are useful for the differentiation from a lymphoma [5, 9]. The average thickness of a pseudocapsule is 3 mm [7, 9, 10]. With respect to MP, the literature predominantly contains case reports. The frequency of MP is specified in the literature with a range from 0.16% to 7.83%. In a prospective study including 7620 patients, Daskalogianaki et al. diagnosed MP in 49 patients (0.6%). A retrospective study by Gögebakan et al. showed a similar prevalence (0.58% of a total of 13485 patients) [10]. The lowest prevalence for MP is seen in a New Zealand study: 0.16% of the study population over a period of 8 years [1]. A limit of the study design of Gögebakan et al. and Wilkes et al. is the use of a keyword-based search method to search for MP in databases. Kuhrmeier identified mesenteric lipodystrophy with typical macroscopic and histopathological changes of the mesenteric adipose tissue in 9 of 712 autopsies (1.26%) [16]. In a prospective evaluation of CT scans of 613 patients, the workgroup of Coulier showed a prevalence of 7.83%. They postulated that the reason for this higher prevalence of MP compared to earlier studies could be explained by advances in CT technology with the increasing use of multidetector CT [8]. Canyigit et al. published a prevalence of 2.43% in 2100 retrospectively evaluated patients [7]. In the present study, 143 cases of MP in a retrospectively evaluated cohort of 5595 patients (2.55%) were identified. There was a histopathologically confirmed malignancy in 107 of these 143 cases (74.8%). Therefore, in our cohort MP occurred significantly more frequently in the presence of an oncological disease. The most common tumor entity associated with MP in our patient population was non-Hodgkin lymphoma (NHL). Daskalogianaki et al. described a concomitant oncological disease in 34 patients with MP (69.3%). NHL was the most frequently seen malignant disease associated with MP [9]. Wilkes et al. identified a tumor association in 38% of MP cases. The most common tumor entity in this study was colorectal cancer followed by
with MP (prostate and pancreatic cancers were also often associated 22.6 % of our lymphoma patients. Colorectal, bronchial, 
and lymphoma [1]. Canyigit et al. and Akram et al. described a relatively low association between MP and a malignant disease (17.6 % and 13 %, respectively) [6, 7]. In the retrospective case-control study by Gögebakan et al., a concomitant tumor disease was detected in 50.6 % of patients with MP-related changes. The majority of these cases were categorized as mild and moderate according to Coulier. More patients in the control group had a malignant disease (61.2 %). No significant relationship between tumor disease and the occurrence of MP was determined based on the data of this cohort [10]. In our cohort with a tumor disease and the occurrence of MP was determined based on the data of this cohort [10]. In our cohort with a tumor disease 

Table 3 Frequencies of the criteria of MP in CT in relation to frequently occurring tumor entities and the non-oncological group.

<table>
<thead>
<tr>
<th>Tumor Entity</th>
<th>Number/Total</th>
<th>Mesentery with milk-glass appearance</th>
<th>Number of nodules [%]</th>
<th>“Fat-ring sign” or halo sign</th>
<th>Pseudocapsule space-occupying effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHL</td>
<td>29/128 (22.6 %)</td>
<td>29/29 (100 %)</td>
<td>29/29 (100 %) 8.01 mm +/- 4.33 3 – 15 mm</td>
<td>12/29 (41 %) 7.28 +/- 4.26 mm 3 – 15 mm</td>
<td>29/29 (41 %) 7.28 +/- 4.26 mm 3 – 15 mm</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>20/452 (4.4 %)</td>
<td>20/20 (100 %)</td>
<td>20/20 (100 %) 7.45 mm +/- 4.08 mm 3 – 15 mm</td>
<td>10/20 (50 %) 7.45 mm +/- 4.08 mm 3 – 15 mm</td>
<td>10/20 (50 %) 7.45 mm +/- 4.08 mm 3 – 15 mm</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>11/180 (6.1 %)</td>
<td>11/11 (100 %)</td>
<td>11/11 (100 %) 8.54 mm +/- 4.08 mm 3 – 15 mm</td>
<td>7/11 (63.3 %) 8.54 mm +/- 4.08 mm 3 – 15 mm</td>
<td>7/11 (63.3 %) 8.54 mm +/- 4.08 mm 3 – 15 mm</td>
</tr>
<tr>
<td>Bronchial cancer</td>
<td>7/64 (5.5 %)</td>
<td>7/7 (100 %)</td>
<td>7/7 (100 %) 8.5 mm +/- 4.51 mm 3 – 15 mm</td>
<td>5/7 (71.4 %) 7.45 mm +/- 4.08 mm 3 – 15 mm</td>
<td>5/7 (71.4 %) 7.45 mm +/- 4.08 mm 3 – 15 mm</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>7/64 (10.9 %)</td>
<td>7/7 (100 %)</td>
<td>7/7 (100 %) 8.5 mm +/- 4.51 mm 3 – 15 mm</td>
<td>5/7 (71.4 %) 7.45 mm +/- 4.08 mm 3 – 15 mm</td>
<td>5/7 (71.4 %) 7.45 mm +/- 4.08 mm 3 – 15 mm</td>
</tr>
<tr>
<td>Non-oncological group</td>
<td>36/3621 (0.99 %)</td>
<td>36/36 (100 %)</td>
<td>36/36 (100 %) 7.5 mm +/- 3.71 mm 3 – 15 mm</td>
<td>25/36 (69.4 %) 7.5 mm +/- 3.71 mm 3 – 15 mm</td>
<td>25/36 (69.4 %) 7.5 mm +/- 3.71 mm 3 – 15 mm</td>
</tr>
</tbody>
</table>

Table 3 Frequencies of the criteria of MP in CT in relation to frequently occurring tumor entities and the non-oncological group.

The prevalence for MP in the onco-

In the patient group without a tumor disease (1974), 107 patients showed MP-related changes. In our cohort (100 %) 7.28 +/- 4.26 mm 3 – 15 mm | 6/7 (85.7 %) 7.28 +/- 4.26 mm 3 – 15 mm |
| Non-oncological group   | 36/3621 (0.99 %) | 36/36 (100 %)                      | 36/36 (100 %) 7.5 mm +/- 3.71 mm 3 – 15 mm | 25/36 (69.4 %) 7.5 mm +/- 3.71 mm 3 – 15 mm | 25/36 (69.4 %) 7.5 mm +/- 3.71 mm 3 – 15 mm |

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
References